• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aspect Biosystems, JDRF partner to develop bioengineered tissue for type 1 diabetes

April 6, 2022 By Sean Whooley

aspect biosystemsAspect Biosystems announced today that it entered into a partnership with the Juvenile Diabetes Research Foundation (JDRF).

The partnership will support Aspect’s focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chronic immune suppression.

Vancouver, British Columbia-based Aspect said in a news release that, in addition to financial support for the development efforts, JDRF will contribute strategic support through its expertise and network in the diabetes space.

Using proprietary bioprinting technology, therapeutic cells and materials science, Aspect is developing a pipeline of cell-based tissue therapeutics for replacing or repairing damaged organ functions.

“Together with JDRF, we are aligned on the mission to develop a curative therapy for the millions of patients around the world who are affected by type 1 diabetes,” Aspect Biosystems CEO Tamer Mohamed said in the release. “This partnership will help advance our cutting-edge pancreatic tissue program and bring us a step closer to human trials.”

The company said its therapeutics are rationally engineered to be biologically functional, immune-protective and suitable for surgical implantation in the treatment of diseases such as type 1 diabetes.

“For more than 20 years, JDRF has been a leader in cell-based tissue therapy research for type 1 diabetes,” JDRF Assistant VP of Research Esther Latres said. “This funding partnership with Aspect Biosystems will support and continue scientific advancements in the field and undeniably take us closer to finding a cure.”

Filed Under: Diabetes, Featured, Regenerative Medicine Tagged With: Aspect Biosystems, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS